New drug aims to stop blood clots during dialysis
NCT ID NCT07201467
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a drug called KN060 in 12 adults with end-stage kidney disease who are on regular hemodialysis. The goal is to see if KN060 is safe and can prevent blood clots from forming in the dialysis machine or the patient's blood vessels. Participants will receive the drug every two weeks for 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KN060 (a drug to prevent blood clots)
What this could lead to
If successful, KN060 could help prevent dangerous blood clots in dialysis machines and fistulas, making dialysis safer for kidney patients.
What could go wrong
This is a very early, small trial (12 people) focused on safety. The drug may not work as hoped, and side effects like bleeding are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE REQUIRING HAEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••